New resistance mechanism in the often multidrug resistant pathogen Acinetobacter baumannii

April 30, 2018, American Society for Microbiology

A team of Australian and Portuguese investigators has discovered yet another resistance mechanism in the pathogen, Acinetobacter baumannii, in this case, one that blocks the critical antibiotic-of-last-resort, colistin. A. baumannii is a highly troublesome pathogen globally, infecting primarily patients in intensive care units with ventilator-associated pneumonia, blood stream infections, and urinary tract infections. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

The genesis of the research was the discovery by Portuguese clinicians that A. baumannii from a bloodstream remained in an elderly patient even after treatment. "Colistin was being used as a last-resort treatment as the strain was highly multidrug resistant," the patient having already been treated with six different antibiotics, said corresponding author John Boyce, PhD, BSc (Hons).

"The infection could not be cleared as the strain developed high-level colistin resistance during treatment," said Dr. Boyce, who is Associate Professor, Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Microbiology, Monash University, Melbourne, Australia. "The clinicians wanted to understand how the strain had become highly colistin resistant, so we determined whole genome sequences of the pre- and post-treatment isolates." (Dr. Boyce's conversations with these clinicians at a conference in Rome led to the collaboration on this research.)

The investigators then compared those sequences to identify the genetic changes associated with the acquisition of high-level colistin resistance. They found only one difference: a gene called hns had been disrupted by an insertion sequence element (a piece of DNA that can insert itself into a chromosome), preventing normal expression. The hns gene encodes a protein that regulates gene transcription. Disrupting such a transcription regulator would change expression of many other genes in the bacteria.

To determine how disruption of the regulatory gene, hns affected colistin resistance, the researchers compared transcription products of from pre- and post-treatment isolates. Expression of a gene that can boost colistin resistance had increased post-treatment.

Dr. Boyce and his collaborators performed several additional experiments that confirmed that the disruption of hns was responsible for the resistance, including inactivating hns in the non-resistant strain, which caused that strain to become "highly colistin resistant," said Dr. Boyce.

"Colistin is a 'last resort' antibiotic that is generally used to treat infections caused by bacteria that are resistant to all other antibiotics," said Dr. Boyce. "Development of colistin resistance in that are already multidrug resistant is incredibly alarming; the threat of pan-resistant infections is very real... development of high-level colistin resistance in this instance played a major role in treatment failure and led to an infection that could not be resolved (although the patient had other comorbidities)."

"Understanding the mechanisms behind development of resistance in clinical settings can allow us to identify treatments that minimize or circumvent , or will in future allow us to develop drugs that target the regulatory systems that control ," said Dr. Boyce.

Explore further: Even short travel can spread colistin-resistant bacteria

Related Stories

Even short travel can spread colistin-resistant bacteria

April 12, 2018
The emergence of antibiotic resistance among dangerous pathogens is increasingly problematic worldwide. Many strains of infectious bacteria have become multidrug-resistant, and cannot be treated with common antibiotic therapies. ...

Bacteria resistant to last-resort antibiotic, missed by standard tests

March 6, 2018
Emory microbiologists have detected "heteroresistance" to colistin, a last-resort antibiotic, in already highly resistant Klebsiella pneumoniae, a bacterium that causes blood, soft tissue and urinary tract infections.

Researchers discover novel colistin resistance gene mcr-3 in Escherichia coli

June 27, 2017
Researchers have now discovered a new mobile colistin resistance gene, mcr-3, in E. coli of pig origin. The novel mcr-3 gene was discovered when a colistin-resistant Escherichia coli isolate tested negative for both mcr-1 ...

First discovery in United States of colistin resistance in a human E. coli infection

May 26, 2016
The Multidrug Resistant Organism Repository and Surveillance Network (MRSN) at the Walter Reed Army Institute of Research (WRAIR) characterized a transferrable gene for colistin resistance in the United States that may herald ...

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.